Cargando…
Next Steps for Immunotherapy in Glioblastoma
SIMPLE SUMMARY: Prognosis for glioblastoma patients remains poor despite the current standard of care treatments. More recent investigations have focused on immunotherapy, which utilizes a patient’s immune system to target cancer cells. Though proven to be successful in non-central nervous system ca...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406905/ https://www.ncbi.nlm.nih.gov/pubmed/36011015 http://dx.doi.org/10.3390/cancers14164023 |
_version_ | 1784774235492712448 |
---|---|
author | Cao, Toni Q. Wainwright, Derek A. Lee-Chang, Catalina Miska, Jason Sonabend, Adam M. Heimberger, Amy B. Lukas, Rimas V. |
author_facet | Cao, Toni Q. Wainwright, Derek A. Lee-Chang, Catalina Miska, Jason Sonabend, Adam M. Heimberger, Amy B. Lukas, Rimas V. |
author_sort | Cao, Toni Q. |
collection | PubMed |
description | SIMPLE SUMMARY: Prognosis for glioblastoma patients remains poor despite the current standard of care treatments. More recent investigations have focused on immunotherapy, which utilizes a patient’s immune system to target cancer cells. Though proven to be successful in non-central nervous system cancers, immunotherapies have yielded disappointing results for glioblastoma thus far. A variety of factors play into the efficacy of immunotherapy for glioblastoma and have become new areas of interest. Here we review both historical and emerging immunotherapeutic approaches, as well as the molecular factors that have been shown to impact the efficacy of immunotherapies. ABSTRACT: Outcomes for glioblastoma (GBM) patients undergoing standard of care treatment remain poor. Here we discuss the portfolio of previously investigated immunotherapies for glioblastoma, including vaccine therapy and checkpoint inhibitors, as well as novel emerging therapeutic approaches. In addition, we explore the factors that potentially influence response to immunotherapy, which should be considered in future research aimed at improving immunotherapy efficacy. |
format | Online Article Text |
id | pubmed-9406905 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94069052022-08-26 Next Steps for Immunotherapy in Glioblastoma Cao, Toni Q. Wainwright, Derek A. Lee-Chang, Catalina Miska, Jason Sonabend, Adam M. Heimberger, Amy B. Lukas, Rimas V. Cancers (Basel) Review SIMPLE SUMMARY: Prognosis for glioblastoma patients remains poor despite the current standard of care treatments. More recent investigations have focused on immunotherapy, which utilizes a patient’s immune system to target cancer cells. Though proven to be successful in non-central nervous system cancers, immunotherapies have yielded disappointing results for glioblastoma thus far. A variety of factors play into the efficacy of immunotherapy for glioblastoma and have become new areas of interest. Here we review both historical and emerging immunotherapeutic approaches, as well as the molecular factors that have been shown to impact the efficacy of immunotherapies. ABSTRACT: Outcomes for glioblastoma (GBM) patients undergoing standard of care treatment remain poor. Here we discuss the portfolio of previously investigated immunotherapies for glioblastoma, including vaccine therapy and checkpoint inhibitors, as well as novel emerging therapeutic approaches. In addition, we explore the factors that potentially influence response to immunotherapy, which should be considered in future research aimed at improving immunotherapy efficacy. MDPI 2022-08-20 /pmc/articles/PMC9406905/ /pubmed/36011015 http://dx.doi.org/10.3390/cancers14164023 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Cao, Toni Q. Wainwright, Derek A. Lee-Chang, Catalina Miska, Jason Sonabend, Adam M. Heimberger, Amy B. Lukas, Rimas V. Next Steps for Immunotherapy in Glioblastoma |
title | Next Steps for Immunotherapy in Glioblastoma |
title_full | Next Steps for Immunotherapy in Glioblastoma |
title_fullStr | Next Steps for Immunotherapy in Glioblastoma |
title_full_unstemmed | Next Steps for Immunotherapy in Glioblastoma |
title_short | Next Steps for Immunotherapy in Glioblastoma |
title_sort | next steps for immunotherapy in glioblastoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406905/ https://www.ncbi.nlm.nih.gov/pubmed/36011015 http://dx.doi.org/10.3390/cancers14164023 |
work_keys_str_mv | AT caotoniq nextstepsforimmunotherapyinglioblastoma AT wainwrightdereka nextstepsforimmunotherapyinglioblastoma AT leechangcatalina nextstepsforimmunotherapyinglioblastoma AT miskajason nextstepsforimmunotherapyinglioblastoma AT sonabendadamm nextstepsforimmunotherapyinglioblastoma AT heimbergeramyb nextstepsforimmunotherapyinglioblastoma AT lukasrimasv nextstepsforimmunotherapyinglioblastoma |